TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.

ABSTRACT:

Background

TP53 is the most commonly mutated gene across all cancer types. R175H mutation was considered structural mutation where the mutation causes misfolding of the protein and leads to a significant conformational alterations within p53's DNA binding domain. The aim of this study was to explain the reason why R175H worse the response to immunotherapy by analyzing tumor immune microenvironment through the expression of immune cells and PD-1.

Materials and methods

Patients diagnosed with metastatic carcinoma, including colorectal cancer (CRC), breast cancer (BRCA), gastric cancer (GC), non-small cell lung cancer (NSCLC), and 20 other cancer types, treated in a palliative setting at Samsung Medical Center between October 2019 and April 2021, were enrolled. Of these patient

SUBMITTER: Kim JY 

PROVIDER: S-EPMC10278489 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature